173 related articles for article (PubMed ID: 12825936)
21. Synthesis and antitumour activities of quinolone antineoplastic agents.
Chu DT; Hallas R; Clement JJ; Alder J; McDonald E; Plattner JJ
Drugs Exp Clin Res; 1992; 18(7):275-82. PubMed ID: 1338309
[TBL] [Abstract][Full Text] [Related]
22. Synthesis of DNA-directed pyrrolidinyl and piperidinyl confined alkylating chloroalkylaminoanthraquinones: potential for development of tumor-selective N-oxides.
Pors K; Shnyder SD; Teesdale-Spittle PH; Hartley JA; Zloh M; Searcey M; Patterson LH
J Med Chem; 2006 Nov; 49(24):7013-23. PubMed ID: 17125254
[TBL] [Abstract][Full Text] [Related]
23. Synthesis of podophyllotoxin congeners as potential DNA topoisomerase II inhibitors.
Kamal A; Atchison K; Daneshtalab M; Micetich RG
Anticancer Drug Des; 1995 Oct; 10(7):545-54. PubMed ID: 7495478
[TBL] [Abstract][Full Text] [Related]
24. Design and synthesis of modified quinolones as antitumoral acridones.
Tabarrini O; Cecchetti V; Fravolini A; Nocentini G; Barzi A; Sabatini S; Miao H; Sissi C
J Med Chem; 1999 Jun; 42(12):2136-44. PubMed ID: 10377219
[TBL] [Abstract][Full Text] [Related]
25. The quinobenzoxazines: relationship between DNA binding and biological activity.
Kwok Y; Sun D; Clement JJ; Hurley LH
Anticancer Drug Des; 1999 Oct; 14(5):443-50. PubMed ID: 10766299
[TBL] [Abstract][Full Text] [Related]
26. Self-assembly of a quinobenzoxazine-Mg2+ complex on DNA: a new paradigm for the structure of a drug-DNA complex and implications for the structure of the quinolone bacterial gyrase-DNA complex.
Fan JY; Sun D; Yu H; Kerwin SM; Hurley LH
J Med Chem; 1995 Feb; 38(3):408-24. PubMed ID: 7853333
[TBL] [Abstract][Full Text] [Related]
27. Antitumor psoropermum xanthones and sarcomelicope acridones: privileged structures implied in DNA alkylation.
Nguyen HT; Lallemand MC; Boutefnouchet S; Michel S; Tillequin F
J Nat Prod; 2009 Mar; 72(3):527-39. PubMed ID: 19191562
[TBL] [Abstract][Full Text] [Related]
28. Molecular modelling studies, synthesis and biological activity of a series of novel bisnaphthalimides and their development as new DNA topoisomerase II inhibitors.
Filosa R; Peduto A; Micco SD; Caprariis Pd; Festa M; Petrella A; Capranico G; Bifulco G
Bioorg Med Chem; 2009 Jan; 17(1):13-24. PubMed ID: 19058969
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells.
Pors K; Paniwnyk Z; Ruparelia KC; Teesdale-Spittle PH; Hartley JA; Kelland LR; Patterson LH
J Med Chem; 2004 Mar; 47(7):1856-9. PubMed ID: 15027879
[TBL] [Abstract][Full Text] [Related]
30. Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II.
Hasinoff BB; Wu X; Begleiter A; Guziec LJ; Guziec F; Giorgianni A; Yang S; Jiang Y; Yalowich JC
Cancer Chemother Pharmacol; 2006 Jan; 57(2):221-33. PubMed ID: 16010589
[TBL] [Abstract][Full Text] [Related]
31. Antitumor agents. 3. Design, synthesis, and biological evaluation of new pyridoisoquinolindione and dihydrothienoquinolindione derivatives with potent cytotoxic activity.
Bolognese A; Correale G; Manfra M; Lavecchia A; Mazzoni O; Novellino E; La Colla P; Sanna G; Loddo R
J Med Chem; 2004 Feb; 47(4):849-58. PubMed ID: 14761187
[TBL] [Abstract][Full Text] [Related]
32. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
33. Structure-based rationalization of antitumor drugs mechanism of action by a MIF approach.
Cruciani G; Benedetti P; Caltabiano G; Condorelli DF; Fortuna CG; Musumarra G
Eur J Med Chem; 2004 Mar; 39(3):281-9. PubMed ID: 15051177
[TBL] [Abstract][Full Text] [Related]
34. Synthesis of 6-chloroisoquinoline-5,8-diones and pyrido[3,4-b]phenazine-5,12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity.
Kim JS; Rhee HK; Park HJ; Lee IK; Lee SK; Suh ME; Lee HJ; Ryu CK; Choo HY
Bioorg Med Chem; 2007 Jan; 15(1):451-7. PubMed ID: 17035025
[TBL] [Abstract][Full Text] [Related]
35. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
[TBL] [Abstract][Full Text] [Related]
36. Topoisomerase II antagonism and anticancer activity of coordinated derivatives of [RuCl(2)(C(6)H(6))(dmso)].
Vashisht Gopal YN; Konuru N; Kondapi AK
Arch Biochem Biophys; 2002 May; 401(1):53-62. PubMed ID: 12054487
[TBL] [Abstract][Full Text] [Related]
37. Chromophore-modified bisnaphthalimides: DNA recognition, topoisomerase inhibition, and cytotoxic properties of two mono- and bisfuronaphthalimides.
Bailly C; Carrasco C; Joubert A; Bal C; Wattez N; Hildebrand MP; Lansiaux A; Colson P; Houssier C; Cacho M; Ramos A; Braña MF
Biochemistry; 2003 Apr; 42(14):4136-50. PubMed ID: 12680768
[TBL] [Abstract][Full Text] [Related]
38. Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones.
Rhee HK; Park HJ; Lee SK; Lee CO; Choo HY
Bioorg Med Chem; 2007 Feb; 15(4):1651-8. PubMed ID: 17194596
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and cancer cell cytotoxicity of substituted xanthenes.
Giri R; Goodell JR; Xing C; Benoit A; Kaur H; Hiasa H; Ferguson DM
Bioorg Med Chem; 2010 Feb; 18(4):1456-63. PubMed ID: 20129790
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, biological evaluation and QSAR studies of novel bisepipodophyllotoxins as cytotoxic agents.
Kamal A; Laxman E; Khanna GB; Reddy PS; Rehana T; Arifuddin M; Neelima K; Kondapi AK; Dastidar SG
Bioorg Med Chem; 2004 Aug; 12(15):4197-209. PubMed ID: 15246096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
